Biomarkers of sepsis.

Détails

ID Serval
serval:BIB_F4175E2DAB90
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Biomarkers of sepsis.
Périodique
Critical Care Medicine
Auteur⸱e⸱s
Marshall J.C., Reinhart K., International Sepsis Forum
Contributeur⸱rice⸱s
International Sepsis Forum, Marshall JC., Reinhart K., Abraham E., Annane D., Calandra T., Cook DJ., Dellinger RP., Dhainaut JF., Hébert P., Heyland D., Moldawer L., Moreno R., Opal S., Stüber F., Vincent JL., Volk HD.
ISSN
1530-0293 (Electronic)
ISSN-L
0090-3493
Statut éditorial
Publié
Date de publication
2009
Volume
37
Numéro
7
Pages
2290-2298
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Résumé
BACKGROUND: A complex network of biological mediators underlies the clinical syndrome of sepsis. The nonspecific physiologic criteria of sepsis syndrome or the systemic inflammatory response syndrome do not adequately identify patients who might benefit from either conventional anti-infective therapies or from novel therapies that target specific mediators of sepsis. Validated biomarkers of sepsis may improve diagnosis and therapeutic decision making for these high-risk patients.
OBJECTIVES: To develop a methodologic framework for the identification and validation of biomarkers of sepsis.
METHODS: A small group meeting of experts in clinical epidemiology, biomarker development, and sepsis clinical trials; selective narrative review of the biomarker literature.
RESULTS: The utility of a biomarker is a function of the degree to which it adds value to the available clinical information in the domains of screening, diagnosis, risk stratification, and monitoring of the response to therapy. We identified needs for greater standardization of biomarker methodologies, greater methodologic rigor in biomarker studies, wider integration of biomarkers into clinical studies (in particular, early phase studies), and increased collaboration among investigators, pharmaceutical industry, biomarker industry, and regulatory agencies.
CONCLUSIONS: Biomarkers promise to transform sepsis from a physiologic syndrome to a group of distinct biochemical disorders. This transformation could aid therapeutic decision making, and hence improve the prognosis for patients with sepsis, but will require an unprecedented degree of systematic investigation and collaboration.
Mots-clé
Biological Markers/metabolism, Humans, Outcome and Process Assessment (Health Care), Predictive Value of Tests, Reproducibility of Results, Risk Assessment, Sepsis/diagnosis, Sepsis/metabolism
Pubmed
Web of science
Création de la notice
03/02/2010 9:56
Dernière modification de la notice
20/08/2019 17:21
Données d'usage